|
|
2024's Stock Market Performance
|
|
2024's Stock Market Performance
|
2024's Large Cap Stocks Performance
Here are the best and worst performing Large-Cap Stocks of 2024.
The Large-Cap Company is defined with the market capitalization, trading above 5 billion dollars U.S. as of 10/03/26.
2024's Mid Cap Stocks Performance
Here are the best and worst performing companies of 2024 with the market capitalization, trading between 500 million U.S. dollars and 5 billion dollars U.S. respectively, as of 10/03/26.
2024's Small Cap Stocks Performance
The table shows the best and worst performing companies of 2024 with the market capitalization, trading between 50 million U.S. dollars and 500 million dollars U.S. respectively, as of 10/03/26.
2024's Micro Cap Stocks Performance
The list shows the best and worst performing companies of 2024 with the market capitalization, trading under 50 million U.S. dollars, as of 10/03/26.
Who are the 2024's Stock Market Losers?
STTK
-83.99%
|
|
|
Shattuck Labs Inc
Major Pharmaceutical Preparations Industry
STTK
-83.99%
Shattuck Labs Inc operates through a platform-based business model, focusing on the development of biotechnology products and solutions. By utilizing its proprietary technology and expertise, the company aims to create innovative therapies targeting various diseases and disorders, ultimately improving patient outcomes. Shattuck Labs Inc collaborates with strategic partners and stakeholders to advance its pipeline, aiming to commercialize its novel treatments and drive growth in the biotech industry.
|
TOVX
-84.09%
|
|
|
Theriva Biologics inc
Major Pharmaceutical Preparations Industry
TOVX
-84.09%
Theriva Biologics Inc operates as a biotechnology company that focuses on the discovery, development, and commercialization of innovative and targeted therapies for various diseases. Their business model is centered around research and development, aiming to create new biologic drugs and bring them to the market to address unmet medical needs.
|
GNLX
-84.11%
|
|
|
Genelux Corporation
Major Pharmaceutical Preparations Industry
GNLX
-84.11%
Genelux Corporation*s business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.
|
SISI
-84.27%
|
|
|
Shineco Inc
Agricultural Production Industry
SISI
-84.27%
Shineco Inc*s business model revolves around cultivating and processing traditional Chinese medicinal herbs and other agricultural products, which are then marketed and sold both domestically and internationally. They aim to leverage their expertise in herbal agriculture to meet the increasing demand for natural, healthy, and sustainable products.
|
PAVM
-84.53%
|
|
|
Pavmed Inc
Medical Equipment & Supplies Industry
PAVM
-84.53%
Pavmed Inc is a medical device company that focuses on developing and commercializing innovative products for various medical fields. The company*s business model revolves around identifying unmet medical needs, acquiring proprietary rights to potential products, and advancing them through development stages to obtain regulatory approvals and market them.
|
ERNA
-84.57%
|
|
|
Ernexa Therapeutics Inc
Major Pharmaceutical Preparations Industry
ERNA
-84.57%
Eterna Therapeutics Inc is a biotechnology company that operates in the field of RNA therapeutics. Their business model focuses on developing innovative RNA-based therapies for various diseases by leveraging their proprietary platform technology. They aim to utilize their scientific expertise and strategic collaborations to advance the discovery, development, and commercialization of RNA therapeutics to improve patient outcomes.
|
WOLF
-84.60%
|
|
|
Wolfspeed Inc
Semiconductors Industry
WOLF
-84.60%
is an innovator of wide bandgap semiconductors
|
QCLS
-84.67%
|
|
|
Qc Technologies Inc
In Vitro & In Vivo Diagnostic Substances Industry
QCLS
-84.67%
Q/C Technologies develops and commercializes laser-based computing systems for blockchain and artificial intelligence applications.
|
DRMA
-84.75%
|
|
|
Dermata Therapeutics Inc
Major Pharmaceutical Preparations Industry
DRMA
-84.75%
Dermata Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing dermatology and skin care products, focusing on innovative treatments for various skin conditions.
|
AIXC
-84.80%
|
|
|
Aixcrypto Holdings Inc
Miscellaneous Financial Services Industry
AIXC
-84.80%
AIxCrypto Holdings develops software focused on tokenizing real-world assets and deploying embodied artificial intelligence.
|
CTNT
-84.82%
|
|
|
Cheetah Net Supply Chain Service inc
Auto & Truck Parts Industry
CTNT
-84.82%
Cheetah Net Supply Chain Service Inc. operates as a third-party logistics provider by creating a marketplace platform that connects shippers with carriers, allowing them to efficiently and effectively manage their supply chain needs. They offer a variety of services such as transportation management, freight brokerage, and e-commerce solutions to streamline and optimize the movement of goods.
|
TNON
-84.84%
|
|
|
Tenon Medical Inc
Medical Equipment & Supplies Industry
TNON
-84.84%
Tenon Medical Inc is a healthcare company that operates on a subscription-based business model, providing medical services and products to subscribers. The company offers a range of medical solutions, including telemedicine consultations, prescription medications, and home delivery of healthcare supplies. Tenon Medical Inc generates revenue through monthly or annual subscription fees, complemented by additional revenue streams from sales of medical products.
|
CBUS
-84.86%
|
|
|
Cibus Inc
Agricultural Production Industry
CBUS
-84.86%
Cibus develops gene-edited traits for major agricultural crops.
|
NCNA
-84.98%
|
|
|
Nucana Plc
Major Pharmaceutical Preparations Industry
NCNA
-84.98%
Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.
|
HEPA
-85.08%
|
|
|
Hepion Pharmaceuticals Inc
Major Pharmaceutical Preparations Industry
HEPA
-85.08%
Hepion Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company, focused on the development of targeted therapies for liver diseases including non-alcoholic steatohepatitis (NASH). The company*s business model revolves around developing innovative drug candidates, conducting clinical trials, and ultimately bringing effective liver disease treatments to market.
|
CVM
-85.13%
|
|
|
Cel sci Corporation
Biotechnology & Pharmaceuticals Industry
CVM
-85.13%
Cel-Sci Corporation*s business model revolves around developing and commercializing immunotherapy drugs for the treatment of infectious diseases and certain types of cancer.
|
|
2,811.36 %
PREV.